PPD Discovery, a wholly-owned subsidiary of PPD, Inc. has established a relationship with New England Biolabs, Inc. (NEB) to produce and sell recombinant human cytochrome P450 (CYP450) enzymes expressed in bacteria using PPD Discovery’s proprietary Pharmazyme technology.
Under the terms of the agreement, NEB receives a non-exclusive license to make and sell human CYP450 enzymes that are expressed in bacteria.
NEB will sell the enzymes under the Pharmazyme trademark and will pay PPD Discovery royalties based on sales.
PPD Discovery will continue to exclusively offer in vitro metabolism services using the Pharmazyme technology.
The patented Pharmazyme technology uses bacterial expression systems to produce human CYP450 enzymes.
The enzymes, which are normally produced in a person’s liver, are used to conduct tests that provide early assessments of safety profiles for drug toxicity, drug-drug interactions and dosing before a product is introduced in the clinical setting.
The tests are performed in vitro, or in a test tube, making them cost-effective.
“We see the agreement with NEB as an excellent fit for PPD Discovery, based on their superior reputation for producing and selling the highest quality enzymes,” said Fred Eshelman, CEO of PPD.
“This relationship enables us to meet client needs for bulk quantities of the CYP450s.”
“NEB is pleased to expand our offering of high quality enzymes into the drug discovery field,” said Larry McReynolds, director of eukaryotic research at NEB. “We look forward to introducing the first in a series of recombinant human CYP450s by early April.”
Established in 1975, NEB is a privately held company with an ongoing commitment to the discovery and production of enzymes for molecular biology applications.
PPD Discovery, the drug discovery technology subsidiary of PPD, Inc., applies functional genomics, integrated chemistry resources and preclinical strategy technologies and expertise in collaboration with biopharmaceutical companies to identify and prioritize novel drug targets and help identify and optimize high quality drug candidates for clinical evaluation.